Is Actemra used for COVID-19 related inflammation?

Is Actemra (tocilizumab) used to treat COVID-19 inflammation?

Yes. Actemra (tocilizumab) is used in some hospitalized COVID-19 patients to treat inflammation driven by an overactive immune response. This use is aimed at conditions like cytokine release syndrome and other severe inflammatory states seen in serious COVID-19 illness. [1]

What kind of COVID-19 patients get Actemra?

Actemra is typically considered for hospitalized patients with severe or critical COVID-19 who show evidence of significant systemic inflammation. Exact eligibility depends on the clinical setting and treatment protocol being followed at the treating hospital. [1]

Is Actemra the same as a general anti-inflammatory, or is it targeted?

It is targeted. Actemra is an anti–IL-6 receptor therapy, designed to reduce inflammatory signaling mediated by interleukin-6, which is involved in the inflammatory cascade seen in severe COVID-19. [1]

How does Actemra fit alongside other COVID-19 treatments?

Actemra is used as an add-on immunomodulatory treatment when inflammation is a dominant driver of illness. It is generally considered in combination with other standard-of-care treatments for severe COVID-19 depending on patient factors and institutional guidance. [1]

Sources

[1] https://www.drugs.com/actemra.html